Cite
HARVARD Citation
Javle, M. et al. (n.d.). LBA28Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions. Annals of oncology. p. . [Online].